Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) 77% LOWER; today announced that its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer did not meet its primary endpoint of overall survival.
The analysis, based on 320 evaluable events (patient deaths), showed a hazard ratio of 0.82 with a p value of 0.089.
The stock was also downgraded at Merriman Curhan Ford .
Spherix Incorporated (NASDAQ: SPEX) 72% HIGHER;...
Post new comment